Jan 30, 2018 08:03 am UTC| Business
VANCOUVER, British Columbia, Jan. 30, 2018 -- Sienna Resources (SIE—TSX.v) (A1XCQ0–FSE) (SNNAF—OTCBB) is pleased to announce that initial results have been received from the ongoing magnetic survey work on the Slättberg...
Ahold Delhaize share buyback update
Jan 30, 2018 07:01 am UTC| Business
Zaandam, the Netherlands, January 30, 2018 - Ahold Delhaize has repurchased 2,506,901 of Ahold Delhaize common shares in the period from January 22, 2018 up to and including January 26, 2018. The shares were repurchased at...
FIRE1 Raises EUR 40 Million in Series C Financing
Jan 30, 2018 07:00 am UTC| Business
DUBLIN, Ireland, Jan. 30, 2018 -- Foundry Innovation Research 1, Ltd. (FIRE1), today announced the close of a Series C financing totaling EUR 40 Million. The financing was led by new investor Gilde Healthcare, with the...
In-Orbit Servicing Market Opportunity Exceeds $3 Billion
Jan 30, 2018 07:00 am UTC| Business
CAMBRIDGE, Mass., Jan. 30, 2018 -- NSR’s industry-first In-Orbit Servicing Markets (IoSM) report, released today, finds the nascent in-orbit servicing market poised for growth, and forecasts a total market of over $3B...
NXP Expands Automotive Ethernet Portfolio with new Gigabit Switch and Dual Port PHY
Jan 30, 2018 07:00 am UTC| Business
MUNICH, Germany, Jan. 30, 2018 -- NXP Semiconductors N.V. (NASDAQ:NXPI), the world’s largest supplier of automotive semiconductor solutions1, has announced an expanded Ethernet portfolio which includes the TJA1102 PHY...
Global Low Intensity Sweeteners Market Will Reach USD 1.72 Billion by 2022: Zion Market Research
Jan 30, 2018 06:29 am UTC| Business
Sarasota, FL, Jan. 30, 2018 -- Zion Market Research has published a new report titled “Low Intensity Sweeteners Market by Type (Xylitol, Tagatose, Allulose, Trehalose, Isomaltuolose) by Application (Bakery, Beverages,...
Innate Pharma and MedImmune enter clinical trial collaboration
Jan 30, 2018 06:01 am UTC| Business
Innate Pharma and MEDIMMUnE Enter clinical trial collaboration Innate Pharma and MedImmune will evaluate the combination of Innate Pharma's first-in-class IPH5401 antibody and Imfinzi® (durvalumab) in a Phase...